CEL-SCI (NYSE:CVM) Trading Down 3.9%

CEL-SCI Co. (NYSE:CVM) fell 3.9% on Tuesday . The company traded as low as $1.65 and last traded at $1.71. 154,015 shares were traded during trading, a decline of 51% from the average session volume of 315,321 shares. The stock had previously closed at $1.78.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of CEL-SCI from a “hold” rating to a “sell” rating in a research report on Friday, March 15th.

CEL-SCI Trading Down 3.9 %

The company has a current ratio of 1.26, a quick ratio of 0.78 and a debt-to-equity ratio of 0.75. The company has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $2.17. The firm has a market capitalization of $92.31 million, a price-to-earnings ratio of -2.51 and a beta of 1.29.

CEL-SCI (NYSE:CVM) last posted its earnings results on Wednesday, February 14th. The company reported ($0.14) earnings per share for the quarter. As a group, research analysts forecast that CEL-SCI Co. will post -0.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CVM. Lincoln National Corp grew its position in shares of CEL-SCI by 138.2% during the third quarter. Lincoln National Corp now owns 55,545 shares of the company’s stock worth $69,000 after buying an additional 32,225 shares in the last quarter. Cutter & CO Brokerage Inc. lifted its position in shares of CEL-SCI by 20.5% during the 3rd quarter. Cutter & CO Brokerage Inc. now owns 102,845 shares of the company’s stock worth $129,000 after purchasing an additional 17,500 shares during the last quarter. Black Diamond Financial LLC grew its stake in shares of CEL-SCI by 20.5% during the third quarter. Black Diamond Financial LLC now owns 53,000 shares of the company’s stock worth $66,000 after purchasing an additional 9,000 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in CEL-SCI by 195.1% in the second quarter. BNP Paribas Arbitrage SA now owns 8,280 shares of the company’s stock valued at $37,000 after buying an additional 5,474 shares during the last quarter. Finally, MML Investors Services LLC acquired a new stake in CEL-SCI in the third quarter valued at $31,000. Institutional investors and hedge funds own 12.08% of the company’s stock.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.